Thalidomide (Contergan/Distaval) — the “Safe” Sedative That Deformed 10,000 Babies and Rewrote Drug Law

When Chemie Grünenthal launched thalidomide in West Germany as Contergan on 1 October 1957, it sold the compound as a sedative so safe that a child could swallow the whole bottle without harm, marketed it without prescription, and promoted it specifically to pregnant women for morning sickness; the documented record shows that the drug was instead one of the most powerful human teratogens ever distributed, and that it reached pregnant patients across roughly 46 countries before any company or regulator had required a single study of its effects on the unborn. Thalidomide, sold in the United Kingdom and Commonwealth by the Distillers Company as Distaval and in dozens of other markets under more than forty trade names, was withdrawn in West Germany on 26 November 1961 after the Hamburg pediatrician Widukind Lenz formally linked it to an epidemic of phocomelia — infants born with foreshortened or flipper-like limbs.

The gap between the promise and the harm was total and structural. Grünenthal advertised the drug as “completely safe” and “non-toxic,” yet it had performed no studies of the drug crossing the placenta and no testing in pregnant animals before approval; the standard toxicity tests of the era, measured by acute lethal dose, registered thalidomide as remarkably benign precisely because its danger lay not in poisoning the patient but in disrupting the developing embryo during a narrow window early in pregnancy. The verdict here is therefore plain at the outset: a non-prescription product advertised as harmless to mother and child was, in fact, causing catastrophic limb, ear, eye, and internal-organ malformations, and the absence of reproductive-safety testing meant the signal could only surface after thousands of affected infants had already been born.

The reckoning that followed reshaped how the world licenses medicines. William McBride’s letter in The Lancet on 16 December 1961 and Lenz’s epidemiological work converted a cluster of “mysterious” birth defects into a recognized drug catastrophe. In the United States, the drug was never approved: FDA medical reviewer Frances Oldham Kelsey had refused to clear Richardson-Merrell’s application (trade name Kevadon) for over a year, repeatedly demanding the safety data the company could not supply. The episode produced the Kefauver-Harris Amendments, signed on 10 October 1962, which for the first time required proof of efficacy as well as safety and established the modern controlled-trial regime.

The Contergan name became the permanent byword for what happens when marketing velocity, over-the-counter access, and the complete absence of reproductive testing converge on a vulnerable population — and for how a single regulator’s refusal can avert a national disaster.

Propulsid (cisapride) — the Heartburn Blockbuster Pulled in 2000 After 80 Arrhythmia Deaths

When Janssen Pharmaceutica — the Belgian unit of Johnson & Johnson — announced on 23 March 2000 that it would stop general U.S. marketing of Propulsid, it presented the move as a precaution; the documented record shows a drug the company’s own labels had flagged as potentially lethal since 1995, kept on the open market for five more years while prescriptions ran past thirty million. Propulsid (cisapride) was a gastrointestinal prokinetic approved by the U.S. Food and Drug Administration in 1993 for nighttime heartburn from gastroesophageal reflux. It worked by speeding the gut, but it also blocked a cardiac potassium channel, prolonging the QT interval and, in vulnerable patients, triggering torsades de pointes — a chaotic ventricular arrhythmia that can stop the heart.

The gap between the indication and the harm was the whole tragedy. Cisapride was approved for adult reflux, but its danger concentrated in people who should never have received it: patients taking common interacting drugs — the macrolide antibiotics erythromycin and clarithromycin, the antifungals ketoconazole, itraconazole and fluconazole — that raised cisapride’s blood levels, and patients with underlying cardiac or metabolic risk. By the FDA’s accounting, of the 341 serious arrhythmias and 80 deaths reported through December 1999, roughly 85 percent occurred in patients with a recognized contraindication or risk factor. The drug was, in effect, safe in the population that did not need protecting and dangerous in the population that did.

The verdict is therefore plain at the outset: an approved, widely prescribed heartburn pill killed through interactions its manufacturer and the FDA had named in the label years before the withdrawal, and a meaningful share of the dead were infants and children who received it off-label for colic and reflux even though it was never approved for pediatric use. One observational study of roughly 58,000 premature infants found that about a fifth had been given cisapride.

What followed was a slow regulatory unwind and a mass-tort settlement. Janssen halted general sale effective 14 July 2000, retaining only a tightly controlled limited-access protocol; in 2004 Johnson & Johnson agreed to pay up to $90 million to resolve claims that the drug caused some 300 deaths and nearly 16,000 injuries. Propulsid became the textbook case of a “Dear Doctor” letter and a black box that did not change prescribing fast enough to stop the dying.